New therapy targeting heart failure mechanisms
Official title: PP2A Anchoring Disruptor Therapy in Heart Failure
Funded at Cardiac Rsk3 Inhibitors, LLC · NIH-10687238 · Data updated 2026-11-12
This study is exploring a new way to help people with heart failure by looking at how certain proteins in heart cells work together, and it hopes to improve heart function for patients who are dealing with this condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cardiac Rsk3 Inhibitors, LLC NIH-funded |
| Lab location | 1 site (Los Altos, United States) |
| Project start | September 1, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $1,219,206 |
| NIH project number | 5R44HL158318-03 |
| Project ID | NIH-10687238 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with dilated cardiomyopathy or other forms of heart failure.
✕Less likely to help
Patients with heart failure due to ischemic causes may not benefit from this specific therapeutic approach.
What this research studies
This research investigates a novel therapeutic approach to treat heart failure by targeting specific protein complexes involved in cardiac remodeling. The study focuses on the role of a protein called mAKAPβ and its interaction with protein phosphatase 2A (PP2A) in heart cells. By disrupting these interactions, the research aims to improve heart function and reduce the progression of heart failure. Patients with heart failure or those at risk may benefit from this innovative treatment strategy.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and quality of life for patients suffering from heart failure.
How similar studies have gone: While this approach is innovative, previous research has shown promise in targeting similar molecular pathways for heart failure treatment.
Where this research is happening
-
Cardiac Rsk3 Inhibitors, LLC
Los Altos, United States Active
Researchers
- Principal investigator: Cividini, Federico — Cardiac Rsk3 Inhibitors, LLC
- Study coordinator: Cividini, Federico
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.